Sydney Lupkin

The federal government is in charge of distributing one of the few treatment options for COVID-19: the antiviral drug remdesivir. But how are decisions made about which states need it most?

Moderna, one of the leading horses in the coronavirus vaccine race, has already made deals at between $32 and $37 a dose for some foreign countries. The U.S. price is expected to be lower.

This is the sixth vaccine candidate to join Operation Warp Speed's portfolio, and the largest vaccine deal to date.

The president says the actions will lower drug prices, but policy experts say they will likely offer patients only minimal relief and may take months to implement, if they're implemented at all.

If the company's vaccine candidate pans out, Americans can receive it for free under the deal. The arrangement is part of the U.S. government's push to have a vaccine widely available by January.

Companies that made hats, socks and teddy bears have started producing surgical masks to protect people from COVID-19. Some sellers exaggerate their standing with the Food and Drug Administration.

An experimental COVID-19 medicine that has been shown to shorten the time people with severe illness have to stay in the hospital finally has a price tag that's lower than some analysts expected.

As Operation Warp Speed pushes to develop a COVID-19 vaccine in record time, the number of candidates is being narrowed. The factors guiding the decisions about which projects to fund is unclear.

Gilead Sciences is donating its initial supply of the experimental treatment for COVID-19. The federal government is deciding where the scarce medicine goes, and there are questions about the choices.

Gilead Sciences has committed to donating the initial supply of the experimental antiviral drug. But executives said the company will need to make expanded production of the treatment sustainable.